C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has C4 Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CCCC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CCCC's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how CCCC performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CCCC performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is C4 Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIndustry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%
1 month ago | Simply Wall StWhat Kind Of Investors Own Most Of C4 Therapeutics, Inc. (NASDAQ:CCCC)?
3 months ago | Simply Wall StRead This Before Selling C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares
Is C4 Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CCCC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CCCC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CCCC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CCCC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CCCC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CCCC is overvalued based on its PB Ratio (6.2x) compared to the US Biotechs industry average (3.4x).
How is C4 Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CCCC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CCCC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CCCC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CCCC's revenue (5.9% per year) is forecast to grow slower than the US market (9.5% per year).
High Growth Revenue: CCCC's revenue (5.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CCCC is forecast to be unprofitable in 3 years.
How has C4 Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CCCC is currently unprofitable.
Growing Profit Margin: CCCC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CCCC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CCCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CCCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: CCCC has a negative Return on Equity (-28.59%), as it is currently unprofitable.
How is C4 Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CCCC's short term assets ($322.0M) exceed its short term liabilities ($37.7M).
Long Term Liabilities: CCCC's short term assets ($322.0M) exceed its long term liabilities ($72.6M).
Debt to Equity History and Analysis
Debt Level: CCCC's debt to equity ratio (3.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CCCC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CCCC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CCCC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 81% each year
What is C4 Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CCCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CCCC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CCCC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CCCC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CCCC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andrew Hirsch (49 yo)
Mr. Andrew J. Hirsch is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeutics, Inc s...
CEO Compensation Analysis
Compensation vs Market: Andrew's total compensation ($USD21.27M) is above average for companies of similar size in the US market ($USD3.69M).
Compensation vs Earnings: Insufficient data to compare Andrew's compensation with company performance.
Experienced Management: CCCC's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: CCCC's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: CCCC only recently listed within the past 12 months.
C4 Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: C4 Therapeutics, Inc.
- Ticker: CCCC
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.816b
- Shares outstanding: 48.08m
- Website: https://www.c4therapeutics.com
Number of Employees
- C4 Therapeutics, Inc.
- 490 Arsenal Way
- Suite 200
- United States
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/24 03:51|
|End of Day Share Price||2021/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.